Infliximab for maintenance of remission in Crohn's disease
Referencias
Additional references
Akobeng AK, Zhang D, Gordon M, MacDonald JK. Oral 5‐aminosalicylic acid for maintenance of medically‐induced remission in Crohn's disease. Cochrane Database of Systematic Reviews 2016, Issue 9. [DOI: 10.1002/14651858.CD003715.pub3]
Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nature Reviews. Gastroenterology and Hepatology 2015;12(4):205‐17.
Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down‐regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999;116(1):22‐8.
Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, et al. Mucosal healing predicts sustained clinical remission in patients with early‐stage Crohn's disease. Gastroenterology 2010;138(2):463‐8.
Baumgart DC, Sandborn WJ. Crohn's disease. Lancet 2012;380(9853):1590‐605.
Behm BW, Bickston SJ. Tumor necrosis factor‐alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD006893]
Chande N, Patton PH, Tsoulis DJ, Thomas BS, MacDonald JK. Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2015, Issue 10. [DOI: 10.1002/14651858.CD000067.pub3]
Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine 2010;362(15):1383‐95.
Colombel JF, Feagan BG, Sandborn WJ, Van Assche G, Robinson AM. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflammatory Bowel Diseases 2012;18(2):349‐58.
Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, et al. Long‐term evolution of disease behavior of Crohn's disease. Inflammatory Bowel Diseases 2002;8(4):244‐50.
D'Haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, et al. Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 1999;116(5):1029‐34.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315(7109):629–34.
REMICADE (infliximab) Label. www.accessdata.fda.gov/drugsatfda_docs/label/2011/103772s5295lbl.pdf Accessed 13 November 2016.
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Alonso‐Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924–6.
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359(9317):1541‐9.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐anlayses. BMJ 2003;327(7414):557–60.
Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane‐handbook.org.
Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR, et al. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet 2015;386(10006):1825‐34.
Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, et al. Construction and initial characterization of a mouse‐human chimeric anti‐TNF antibody. Molecular immunology 1993;30(16):1443‐53.
Mitoma H, Horiuchi T, Hatta N, Tsukamoto H, Harashima SI, Kikuchi Y, et al. Infliximab induces potent anti‐inflammatory responses by outside‐to‐inside signals through transmembrane TNF‐alpha. Gastroenterology 2005;128(2):376‐92.
Molodecky NA, Soon S, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142(1):46‐54.
Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scandinavian Journal of Gastroenterology 1995;30(7):699‐706.
Poggioli G, Laureti S, Campieri M, Pierangeli F, Gionchetti P, Ugolini F, et al. Infliximab in the treatment of Crohn's disease. Therapeutics and Clinical Risk Management 2007;3(2):301‐8.
Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointestinal Endoscopy 2006;63(3):433‐42.
Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflammatory Bowel Diseases 1999;5(2):119‐33.
Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. New England Journal of Medicine 2004;350(9):876‐85.
Satsangi J, Silverberg MS, Vermeire S, Colombel J. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55(6):749‐53.
Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. Cochrane Handbook for Systematic Reviewsof Interventions Version 5.1.0. The Cochrane Collaboration, (updated March 2011).
Shah SC, Colombel JF, Sands BE, Narula N. Systematic review with meta‐analysis: mucosal healing is associated with improved long‐term outcomes in Crohn's disease. Alimentary Pharmacology and Therapeutics 2016;43(3):317‐33.
Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO. Corticosteroids for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD000301]
